India’s Ranbaxy Gets U.S. FDA Help In Mylan Generic-Suit Challenge
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories of India has gained the support of the U.S. FDA in its fight to challenge Mylan's introduction of a competitive version of U.S.-based Pfizer's Lipitor's (atorvastatin) cholesterol-lowering drug